泌尿道感染檢測市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、最終用途、地區和競爭細分

2022 年全球泌尿道感染檢測市場價值為 5.6132 億美元，預計到 2028 年預測期內將穩定成長，複合CAGR為 4.25%。泌尿道感染 (UTI) 是影響全球數百萬人的常見疾病，帶來巨大的經濟和醫療負擔。準確、及時的診斷對於有效的治療和患者護理至關重要。這種需求推動了全球尿路感染檢測市場的成長。當有害細菌進入泌尿系統並繁殖時，就會發生泌尿道感染，導致各種症狀，如排尿時疼痛和不適、頻繁尿意，有時甚至發燒。尿路感染可以影響泌尿系統的任何部分，包括膀胱、尿道和腎臟。快速、準確地診斷泌尿道感染對於確定適當的治療方案至關重要，治療方案通常涉及抗生素。

市場概況
預測期	2024-2028
2022 年市場規模	56132萬美元
2028 年市場規模	71244萬美元
2023-2028年CAGR	4.25%
成長最快的細分市場	膀胱炎
最大的市場	北美洲

近年來，在泌尿道感染發病率上升、患者和醫療保健專業人員意識提高以及診斷測試技術進步等多種因素的推動下，全球尿路感染檢測市場出現了顯著成長。市場規模預計將達到相當大的數字，並預測未來幾年將穩定成長。 COVID-19 大流行也凸顯了快速診斷檢測的重要性，這進一步增加了對 UTI 檢測的需求。

即時檢測的轉變是泌尿道感染檢測市場的重要趨勢。即時檢測可快速提供結果，使醫療保健提供者能夠及時開始治療。核酸擴增檢測和先進尿液分析儀等診斷技術的創新提高了泌尿道感染檢測的準確性和效率。尿路感染的家庭檢測套件越來越受歡迎，使患者可以輕鬆地在舒適的家中監測自己的健康狀況。由於新冠肺炎 (COVID-19) 大流行，這一趨勢愈演愈烈，因為人們力求盡量減少前往醫療機構的次數。發展中國家的醫療保健意識和基礎設施不斷增強，導致這些地區的泌尿道感染檢測市場大幅成長。

主要市場促進因素

尿路感染發生率上升正在推動全球尿路感染檢測市場

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球泌尿道感染檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（尿道炎、膀胱炎、腎盂腎炎）
  • 依最終用途（全科醫生 (GP)、泌尿科醫生、泌尿婦科醫生、醫院實驗室、參考實驗室、其他）
  • 按地區
  • 按公司分類 (2022)
• 市場地圖
  • 按類型
  • 按最終用途
  • 按地區

第 5 章：亞太地區泌尿道感染檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按最終用途
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 6 章：歐洲泌尿道感染檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按最終用途
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 7 章：北美泌尿道感染檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按最終用途
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 8 章：南美洲泌尿道感染檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按最終用途
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 9 章：中東和非洲泌尿道感染檢測市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按最終用途
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 10 章：市場動態

• 促進要素
• 挑戰

第 11 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 12 章：全球泌尿道感染檢測市場：SWOT 分析

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• QIAGEN NV
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthcare GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• BIOMERIEUX
• T2 Biosystems, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Urinary Tract Infection Testing Market was valued at USD 561.32 Million in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 4.25% through 2028. Urinary tract infections (UTIs) are a common ailment affecting millions of individuals worldwide, with a substantial economic and healthcare burden. Accurate and timely diagnosis is crucial for effective treatment and patient care. This need has driven the growth of the global Urinary Tract Infection Testing Market. Urinary tract infections occur when harmful bacteria enter the urinary system and multiply, leading to various symptoms such as pain and discomfort during urination, frequent urges to urinate, and in some cases, fever. UTIs can affect any part of the urinary system, including the bladder, urethra, and kidneys. Rapid and accurate diagnosis of UTIs is essential to determine the appropriate treatment regimen, which typically involves antibiotics.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 561.32 Million
Market Size 2028	USD 712.44 Million
CAGR 2023-2028	4.25%
Fastest Growing Segment	Cystitis
Largest Market	North America

The global urinary tract infection testing market has witnessed significant growth in recent years, driven by various factors, including rising UTI incidence, increasing awareness among patients and healthcare professionals, and technological advancements in diagnostic tests. The market size is expected to reach a substantial figure, with projections suggesting steady growth in the coming years. The COVID-19 pandemic has also underscored the importance of rapid diagnostic testing, which has further contributed to the demand for UTI testing.

The shift towards point-of-care testing is a significant trend in the UTI testing market. Point-of-care tests provide quick results, enabling healthcare providers to initiate treatment promptly. Innovations in diagnostic technologies, such as nucleic acid amplification tests and advanced urine analyzers, have improved the accuracy and efficiency of UTI testing. Home testing kits for UTIs are becoming more popular, giving patients the convenience to monitor their health from the comfort of their homes. This trend has gained momentum due to the COVID-19 pandemic, as people seek to minimize healthcare facility visits. Developing countries are witnessing an increase in healthcare awareness and infrastructure, leading to substantial growth in UTI testing markets in these regions.

Key Market Drivers

Rising Urinary tract infections Incidence Rates is Driving the Global Urinary Tract Infection Testing Market

Urinary tract infections (UTIs) are one of the most common bacterial infections worldwide, affecting millions of people each year. While UTIs are typically not life-threatening, they can cause significant discomfort and inconvenience. Moreover, if left untreated, they can lead to more severe health complications. Recent years have seen a notable rise in UTI incidence rates, creating a demand for more efficient diagnostic tools and increasing the global Urinary Tract Infection Testing Market. UTIs are bacterial infections that can affect any part of the urinary system, including the bladder, urethra, and kidneys. The majority of UTIs are caused by Escherichia coli (E. coli) bacteria, but other bacteria can also be responsible. Common symptoms of UTIs include frequent urination, a burning sensation during urination, cloudy or bloody urine, and discomfort in the lower abdomen. Verse and misuse of antibiotics have led to the emergence of antibiotic-resistant strains of bacteria, making UTIs harder to treat. The rising prevalence of multidrug-resistant UTIs necessitates more accurate and prompt diagnosis. Modern lifestyles, such as increased sexual activity and the use of certain types of birth control, can contribute to an increased risk of UTIs. As the global population continues to age, older individuals become more susceptible to UTIs due to weakened immune systems and other age-related factors. Improved education and awareness regarding the symptoms and risks of UTIs may lead to more people seeking medical attention for these infections.

The demand for accurate and efficient UTI diagnostic tools has given rise to a thriving Urinary Tract Infection Testing Market. This market includes a wide range of products and services. Traditional urinalysis remains the most common method for diagnosing UTIs. However, advances in urinalysis techniques have allowed for more accurate and rapid results. Dipstick tests are cost-effective and easy-to-use tools for initial UTI screening. They can quickly detect key indicators of infection, such as nitrites and leukocytes. For complex or recurrent UTIs, microbiological culture tests are crucial for identifying the specific bacteria causing the infection and their antibiotic susceptibility. Advanced technology has made these tests more efficient and precise. Molecular testing methods, like polymerase chain reaction (PCR), can detect UTIs with high sensitivity and specificity. These tests can identify the presence of bacteria and even antibiotic resistance genes. Point-of-Care Testing (POCT) devices have gained popularity as they offer rapid results, allowing healthcare providers to initiate treatment more promptly.

Growing Private and Public Sector Investments is Driving the Global Urinary Tract Infection Testing Market

Private sector investments have been a driving force behind the growth of the global UTI testing market. Pharmaceutical and diagnostic companies have recognized the potential for developing innovative solutions to diagnose and manage UTIs more effectively. These investments are directed towards research and development to create advanced diagnostic tests, antibiotics, and therapeutics to treat UTIs. Companies are increasingly focusing on the development of rapid diagnostic tests that offer quicker and more accurate results, enabling healthcare providers to initiate treatment promptly. For instance, the advent of molecular diagnostics and point-of-care testing devices has revolutionized the way UTIs are diagnosed and managed. These innovations offer higher sensitivity and specificity, reducing the chances of misdiagnosis and unnecessary antibiotic prescriptions. Moreover, private sector investments are also supporting the development of alternative therapies, such as novel antibiotics, which can target drug-resistant UTI-causing bacteria. The rise of antibiotic-resistant bacteria is a growing concern, and addressing this issue is crucial to effectively manage UTIs.

Public sector investments, often in the form of research grants, have been instrumental in fostering academic and government research initiatives aimed at improving UTI diagnosis and treatment. Public health organizations and governmental bodies recognize the economic and public health burden that UTIs pose and are actively investing in programs to reduce the prevalence of these infections. Public health campaigns are promoting awareness about UTIs and the importance of timely diagnosis and treatment. Additionally, governments are funding research into the epidemiology and microbiology of UTIs, leading to a better understanding of the causative agents and their drug resistance patterns. Another key aspect of public sector involvement is the development of guidelines and regulations to ensure the responsible use of antibiotics in UTI treatment. Overuse and misuse of antibiotics have contributed to the development of drug-resistant strains, so regulating antibiotic prescribing practices is essential.

The investments made by both the private and public sectors in UTI testing and management are having a global impact. This is particularly important as UTIs are a widespread issue that knows no borders. Access to accurate diagnostics and effective treatments is improving not only in developed nations but also in resource-limited regions, where the burden of UTIs can be especially high.

Key Market Challenges

Overuse of Antibiotics

One of the major challenges facing the UTI testing market is the overuse of antibiotics, which can lead to the development of antibiotic-resistant strains of bacteria. UTIs are often treated empirically, with antibiotics prescribed before the results of a urine culture are available. This overreliance on antibiotics can contribute to the development of antibiotic-resistant bacteria, making treatment less effective in the long run.

Limited Awareness

While UTIs are common, there is a lack of awareness about the importance of proper testing and early diagnosis. Many individuals may self-diagnose and self-medicate without seeking professional medical advice. This limited awareness can lead to delayed diagnosis and treatment, resulting in more severe infections and complications.

False Positives and Negatives

Urinary tract infection testing methods, including dipstick tests and urinalysis, can yield false positives and false negatives. False positives may lead to unnecessary antibiotic treatment, contributing to antibiotic resistance. On the other hand, false negatives can result in missed diagnoses, leading to untreated infections that can worsen over time. Improving the accuracy of UTI testing methods is a critical challenge for the industry.

Lack of Standardization

The lack of standardized UTI testing procedures is another significant challenge. Different laboratories and healthcare facilities may use varying methods and interpret results differently, making it challenging to ensure consistency in UTI diagnosis. Standardization is crucial to ensure the accuracy and reliability of test results.

Cost Constraints

Cost constraints are a substantial challenge for both patients and healthcare providers. Comprehensive UTI testing, including urine culture and sensitivity testing, can be expensive. In resource-limited settings, cost can be a barrier to proper testing, leading to inadequate diagnosis and treatment.

Emerging Technologies

While new technologies are being developed to improve UTI testing, their adoption can be slow and face resistance from traditional testing methods. Healthcare providers may be hesitant to invest in new technologies due to the cost and the need for staff training. The transition from conventional methods to more advanced and accurate testing technologies is a challenge for industry.

Regulatory Hurdles

The global UTI testing market is subject to various regulatory hurdles, with different countries and regions having their own standards and requirements for diagnostic tests. Meeting these regulatory standards can be time-consuming and costly for manufacturers, hindering the availability of advanced testing methods in some areas.

Telemedicine and Remote Testing

The rise of telemedicine and remote testing options presents both opportunities and challenges. While these technologies can improve access to testing, they also raise concerns about the accuracy of remote testing and the potential for misdiagnosis. Ensuring that remote testing methods are accurate and reliable is a challenge that the industry must address.

Key Market Trends

Technological Advancements

Urinary tract infections (UTIs) are one of the most common bacterial infections affecting people of all ages. They can cause discomfort, pain, and even severe health complications if left untreated. The global urinary tract infection testing market has been evolving rapidly in recent years, thanks to the convergence of medical technology and innovative solutions. This market's growth is significantly driven by advancements in technology that have revolutionized the way UTIs are diagnosed, monitored, and treated.

The development of rapid point-of-care testing for UTIs has been a game-changer in healthcare. These tests are cost-effective, non-invasive, and deliver quick results, allowing for immediate diagnosis and treatment. Such technology often relies on innovative lab-on-a-chip devices, automated urinalysis equipment, and smartphone applications. Patients can now test for UTIs at home or at a clinic, leading to quicker interventions and better patient outcomes. Molecular diagnostic techniques, including polymerase chain reaction (PCR) and nucleic acid amplification, have significantly improved the accuracy and reliability of UTI testing. These methods can identify the specific strain of bacteria causing the infection, enabling healthcare providers to prescribe targeted antibiotics. Molecular diagnostics have also reduced the need for culture-based tests, which can take days to yield results.

The integration of digital health solutions, such as telemedicine and electronic health records, has streamlined the UTI testing process. Patients can consult with healthcare professionals remotely, receive electronic prescriptions, and monitor their condition through smartphone apps. These innovations improve the overall patient experience and reduce the burden on healthcare facilities. Artificial intelligence (AI) and machine learning (ML) algorithms are being used to analyze large datasets of UTI patient information. These technologies can assist healthcare professionals in diagnosing and predicting UTIs more accurately. They also help in the development of personalized treatment plans based on a patient's medical history and specific risk factors. The rise of wearable health devices, including smartwatches and fitness trackers, has also contributed to the growth of the UTI testing market. Some of these devices can monitor vital signs and urinary parameters, providing valuable data that can aid in the early detection of UTIs and prompt intervention.

Segmental Insights

Type Insights

Based on the category of type, Cystitis emerged as the dominant player in the global market for Urinary Tract Infection Testing in 2022. Cystitis, often referred to as a lower UTI, is an infection or inflammation of the bladder. It is commonly caused by bacteria, such as Escherichia coli (E. coli), which can enter the bladder and lead to various symptoms, including frequent and painful urination, a strong urge to urinate, and discomfort in the pelvic region. Cystitis can affect individuals of all ages and genders, but it is more prevalent in women due to their shorter urethras, which make it easier for bacteria to reach the bladder. Accurate and timely diagnosis of cystitis is crucial for effective treatment and the prevention of complications. As a result, the global urinary tract infection testing market has seen a significant shift towards tests and diagnostic tools specifically designed to detect cystitis. Urine culture tests are among the most common methods for diagnosing cystitis. They involve growing and identifying bacteria in a urine sample to determine the cause of the infection. These tests not only confirm the presence of cystitis but also help in identifying the specific bacteria responsible, aiding in the selection of appropriate antibiotics. Rapid diagnostic tests are becoming increasingly popular as they provide quick results, often within minutes. These tests can detect specific proteins or DNA related to cystitis-causing bacteria. Their speed and accuracy are invaluable in clinical settings, allowing for prompt treatment and reducing the risk of complications.

End use Insights

The reference laboratories segment is projected to experience rapid growth during the forecast period. Reference laboratories are equipped with state-of-the-art technology and a wide range of diagnostic services. This includes the ability to perform culture tests, urinalysis, and molecular testing for various strains of bacteria responsible for UTIs. Their comprehensive approach allows for the accurate identification of pathogens and their antibiotic susceptibility profiles. Reference laboratories adhere to strict quality standards and regulations. These standards ensure the accuracy and reliability of test results, critical for patient care and public health. They are often accredited by organizations like the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). Reference laboratories serve multiple healthcare providers, clinics, and hospitals. Their centralized testing approach means that they can handle a large volume of samples efficiently. This not only reduces the turnaround time for results but also offers cost-efficiency for both providers and patients.

Regional Insights

North America emerged as the dominant player in the global Urinary Tract Infection Testing market in 2022, holding the largest market share in terms of value. North America, including the United States and Canada, has consistently reported a high prevalence of urinary tract infections. UTIs are one of the most common bacterial infections in the region, affecting millions of individuals every year. The prevalence of UTIs is driven by various factors, including lifestyle, diet, and healthcare infrastructure. The higher incidence of UTIs has led to a greater demand for UTI testing services. North America boasts some of the most advanced healthcare systems in the world. With well-established hospitals, clinics, and laboratories, the region has the infrastructure to support sophisticated diagnostic testing procedures. Patients have access to a wide range of healthcare services, including UTI testing, which contributes to the high demand for these tests.

Key Market Players

QIAGEN NV

Accelerate Diagnostics, Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd.

Danaher Corporation

Siemens Healthcare GmbH

Randox Laboratories Ltd.

Thermo Fisher Scientific, Inc.

BIOMERIEUX

T2 Biosystems, Inc.

Report Scope:

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urinary Tract Infection Testing Market, By Type:

• Urethritis
• Cystitis
• Pyelonephritis

Urinary Tract Infection Testing Market, By End use:

• Urologists
• Urogynecologists
• Hospital Laboratories
• Reference Laboratories
• Others

Urinary Tract Infection Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Urinary Tract Infection Testing Market.

Available Customizations:

• Global Urinary Tract Infection Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Urinary Tract Infection Testing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Urethritis, Cystitis, Pyelonephritis)
  • 4.2.2. By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By End use
  • 4.3.3. By Region

5. Asia Pacific Urinary Tract Infection Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By End use
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Urinary Tract Infection Testing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By End use
  • 5.3.2. India Urinary Tract Infection Testing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By End use
  • 5.3.3. Australia Urinary Tract Infection Testing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By End use
  • 5.3.4. Japan Urinary Tract Infection Testing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By End use
  • 5.3.5. South Korea Urinary Tract Infection Testing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By End use

6. Europe Urinary Tract Infection Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By End use
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Urinary Tract Infection Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By End use
  • 6.3.2. Germany Urinary Tract Infection Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By End use
  • 6.3.3. Spain Urinary Tract Infection Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By End use
  • 6.3.4. Italy Urinary Tract Infection Testing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By End use
  • 6.3.5. United Kingdom Urinary Tract Infection Testing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By End use

7. North America Urinary Tract Infection Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By End use
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Urinary Tract Infection Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By End use
  • 7.3.2. Mexico Urinary Tract Infection Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By End use
  • 7.3.3. Canada Urinary Tract Infection Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By End use

8. South America Urinary Tract Infection Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End use
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Urinary Tract Infection Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End use
  • 8.3.2. Argentina Urinary Tract Infection Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End use
  • 8.3.3. Colombia Urinary Tract Infection Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End use

9. Middle East and Africa Urinary Tract Infection Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End use
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Urinary Tract Infection Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End use
  • 9.3.2. Saudi Arabia Urinary Tract Infection Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End use
  • 9.3.3. UAE Urinary Tract Infection Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End use

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Urinary Tract Infection Testing Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. QIAGEN NV
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Product & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Accelerate Diagnostics, Inc.
• 14.3. Bio-Rad Laboratories, Inc.
• 14.4. F. Hoffmann-La Roche Ltd.
• 14.5. Danaher Corporation
• 14.6. Siemens Healthcare GmbH
• 14.7. Randox Laboratories Ltd.
• 14.8. Thermo Fisher Scientific, Inc.
• 14.9. BIOMERIEUX
• 14.10. T2 Biosystems, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer